Xenetic Biosciences, Inc. XBIO
1.87 USD +0.07 (+3.68%)
At closeNov 11, 2026, 4:38 PM EST
1.83 -0.04 -1.94%
After hours · Nov 11, 4:38 PM ET
1.77 Day range 1.90
1.58 52-week range 4.94
- YTD
- -14.00%
- 1 year
- -31.64%
News
defenseworld.net Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
benzinga.com Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
accessnewswire.com Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) stock moved upwards by 76.7% to $5.69 during Monday's pre-market session. The market value of their outstanding shares is at $4.8 million. Alector…
defenseworld.net Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR) Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
benzinga.com Crude Oil Down Over 3%; US Business Inventories Surge In July U.S. stocks mixed: Dow slipped 0.1%, Nasdaq rose 0.7%, S&P 0.3%; tech led gains, energy fell, while oil dropped 3.2%.
seekingalpha.com Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
benzinga.com Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective…
benzinga.com Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition Xenetic Biosciences plans to acquire Santersus in an all-stock deal, forming Santersus Bio to tackle NET-driven diseases.
benzinga.com Nasdaq Gains Over 100 Points; US Retail Sales Beat Estimates U.S. stocks edged higher as strong retail sales lifted sentiment; utilities gained, energy fell, oil dropped, while European and Asian markets advanced.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
accessnewswire.com Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care,…
benzinga.com Xenetic Biosciences Q2 EPS $(0.41) Up From $(0.45) YoY, Sales $660.601K Up From $589.897K YoY Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported…
accessnewswire.com Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and…- benzinga.com Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of Health Approval To Conduct An Exploratory Clinical Study Of Combination Systemic DNase I With Anti-CD19 CAR T Cells In Large B Cell Lymphoma Patients This approval follows positive preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination…
accessnewswire.com Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong…- benzinga.com Xenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Activity In B-Cell Cancer Models New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to…
accessnewswire.com Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I…
accessnewswire.com Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty…
benzinga.com Xenetic Biosciences Q1 EPS $(0.20) Up From $(0.59) YoY, Sales $806.923K Up From $593.261K YoY Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 percent increase over losses of $(0.59) per share from the same period last year. The company reported…
accessnewswire.com Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology…
defenseworld.net Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of…
accessnewswire.com Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and…
defenseworld.net Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
defenseworld.net Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 55,692 shares, a…
defenseworld.net Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO) Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will…
defenseworld.net Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX) Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
defenseworld.net Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest…
accessnewswire.com Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
accessnewswire.com Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative…
benzinga.com Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of…
benzinga.com Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
benzinga.com 4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new…
benzinga.com Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Nasdaq Gains 150 Points; US Mortgage Applications Decline - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of…- benzinga.com Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I)…